Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD

Abstract Introduction Although most patients with NAFLD are obese or overweight, some are lean with normal BMI. Our aim was to assess differences in clinicopathological profile and liver disease severity among lean and non-lean NAFLD. Methods Data of 1040 NAFLD patients over last 10 years was analysed. BMI <23kg/m2 categorised lean patients. Non-invasive assessment of steatosis was done by ultrasound and controlled attenuation parameter (CAP) while fibrosis was assessed with FIB-4 and liver stiffness measurement (LSM). FibroScan-AST (FAST) score was used for non-invasive prediction of NASH with significant fibrosis. Histology was reported using NASH-CRN system. Results 149 (14.3%) patients were lean while 891 (85.7%) patients were non-lean. Diabetes mellitus [25 (16.7%) vs 152 (17.05%), p>0.99], elevated triglycerides [81 (54.3%) vs 525 (58.9%), p=0.33] and low HDL [71(47.6%) vs 479(53.7%),p=0.18] were observed in a similar proportion. Lean patients were less likely to have central obesity [72 (48.3%) vs 788 (88.4%),p<0.001], hypertension [16 (10.7%) vs 239(26.8%),p<0.001] and metabolic syndrome [21 (14.09%) vs 290 (32.5%),p<0.001]. No difference in steatosis assessment was noted using ultrasound (p=0.55) or CAP (0.11). FAST [0.38 (0.18-0.66) vs 0.39 (0.27-0.73),p=0.53],FIB-4 [1.08 (0.65-1.91) vs 1.09 (0.66-1.94),p=0.94] and LSM [6.1 (4.8-7.9) vs 6.2 (4.7-8.6),p=0.19) were similar. Liver biopsy was available in 149 patients [lean: 19 (12.7%), non-lean: 130 (87.3%)]. There was no difference in the number of patients with NASH [4 (21.05%) vs 20 (15.3%),p=0.51], significant fibrosis [2 (10.5%) vs 32 (24.6%),p=0.25] or advanced fibrosis [1 (5.26%) vs 18 (13.84%),p=0.47]. Conclusion Although metabolic co-morbidities are less common, there is no difference in liver disease severity among both groups.